The cytotoxicity of a recombinant adenovirus expressing the wild type tumor suppressor
gene p53 (AdWTp53) was studied in two human breast cancer MCF-7 sublines selected for …

We examined p53 protein stability and DNA damage-induced p53-dependent responses in
a human leukemic CEM cell line and two teniposide-resistant sublines, CEM/VM-1 and …

Synergy (or antagonism) between two chemical agents is an in vitro empirical phenomenon,
in which the observed effect of the combination is more (or less) than what would be …

Previous work from this laboratory has demonstrated an association between the
suppression of c-myc expression and the antiproliferative activity of both topoisomerase II …

In contrast to findings in vitro, the clinical response to anticancer chemotherapy is not simply
associated with the p53 mutation status. To analyze the relationship between the actual …

Many tumor types have p53 and/or RB mutations, and it is unclear what role the mutations of
these tumor suppressor genes have on the efficacy of chemotherapeutic agents. The effect …

Mutations of the tumor suppressor wild-type p53 gene have been implicated in the
development of resistance to anticancer drugs. We have examined the role of wild-type p53 …

Clonogenic survival and early cell death during treatment of human colon carcinoma cells
were investigated following X‐irradiation (IR) alone, IR followed by 5‐FU for 24 h, and Taxol …

The present study was performed to gain insight into the role of p53 on the cytotoxicity of
tubulin-binding agents (TBA) on cancer cells. Drug sensitivity, cell cycle distribution and …

We evaluated cell survival, DNA double strand breaks (dsbs), and DNA synthesis following
camptothecin (CPT) alone or concurrent CPT and X‐radiation treatments in exponential …